Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer

Table 3 Univariate and multivariate analyses of prognostic factors for progression-free survival for all patients

Variables	Univariate analyses		Multivariate analyses
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	0.759 (0.554-1.041)	0.087	0.772 (0.529-1.126)	0.179
Age (> 60 vs ≤ 60)	1.162 (0.830-1.626)	0.382	0.955 (0.654-1.395)	0.813
Smoking status (Yes vs No)	0.805 (0.550-1.177)	0.262	1.227 (0.781-1.927)	0.375
Number of involved sites (multiple vs one)	1.484 (1.083-2.034)	0.014	1.223 (0.880-1.701)	0.231
Liver metastasis (Yes vs No)	0.950 (0.674-1.339)	0.770	0.737 (0.506-1.073)	0.112
Bone metastasis (Yes vs No)	1.219 (0.762-1.951)	0.409	1.232 (0.754-2.011)	0.405
Treatment regimens (combination chemotherapy vs others)	0.448 (0.313-0.639)	0.000	0.398 (0.263-0.594)	0.000
AAPR (> 0.48 vs ≤ 0.48)	0.611 (0.446-0.837)	0.002	0.527 (0.370-0.751)	0.000

HR: Hazard ratio; CI: Confidence interval; AAPR: Albumin-to-alkaline phosphatase ratio.